發(fā)布時間：2018-11-22 15:25

【摘要】：目的 探討利培酮合用抗抑郁藥文拉法辛對精神分裂癥陰性癥狀、社會功能恢復的療效。 研究方法 本研究采用隨機分組的方法,將符合CCMD-3精神分裂癥診斷標準的80例患者隨機分為利培酮±文拉法辛組(研究組)和利培酮組(對照組)各40例。其中研究組完成35例,對照組完成36例。治療時間為12周,分別于治療前、治療4周、8周、12周末使用陽性與陰性癥狀量表(the Positive and Negative Syndrome Scale, PANSS)精神病患者社會功能評定量表(Personal and Social Performance, PSP)評估臨床療效,錐體外系反應量表(A Rating Scale for Extrapyramidal Side Effects, RSESE)評估治療副反應。并于治療前、治療4周、8周、12周末行血常規(guī)、血生化及心電圖檢查來評估藥物的安全性 結(jié)果 1.兩組組內(nèi)比較：與治療前相比,研究組與對照組在4周末、8周末、12周末PANSS總分、陽性因子分、陰性因子分、一般精神病理癥狀總分均有顯著下降(P0.05或P0.01)；兩組間比較：研究組與對照組在第12周末PANSS,總分、陰性因子分、一般精神病理癥狀總分差異均有統(tǒng)計學意義(P0.05或P0.01)。 2.兩組組內(nèi)比較：與治療前相比,研究組與對照組在4周末、8周末、12周末PSP總分均有顯著下降(P0.01)；兩組間比較：研究組與對照組在第12周末PSP總分差異有統(tǒng)計學意義(P0.05)。 3.不良反應的發(fā)生率兩組差異無統(tǒng)計學意義(P0.05),不良反應多為輕度,最常見不良反應均為錐體外系反應。 結(jié)論 1.利培酮合用文拉法辛可以改善精神分裂癥患者的陰性癥狀； 2.利培酮合用文拉法辛可以改善精神分裂癥患者社會功能； 3.利培酮合用文拉法辛治療精神分裂癥的安全性較好,具有良好的臨床實用性。
[Abstract]:Objective to investigate the efficacy of risperidone combined with venlafaxine in the recovery of social function and negative symptoms of schizophrenia. Methods 80 patients with CCMD-3 schizophrenia were randomly divided into risperidone 鹵venlafaxine group (study group) and risperidone group (control group). 35 cases were completed in the study group and 36 cases in the control group. The treatment time was 12 weeks. Before treatment, 4 weeks, 8 weeks and 12 weeks of treatment, (Personal and Social Performance, PSP) was used to assess the clinical efficacy of (the Positive and Negative Syndrome Scale, PANSS) psychiatric patients with positive and negative symptoms. Treatment side effects were evaluated by extrapyramidal response scale (A Rating Scale for Extrapyramidal Side Effects, RSESE). Before treatment, 4 weeks, 8 weeks and 12 weeks of treatment, blood routine, blood biochemistry and electrocardiogram were used to evaluate the safety of the drug. 1. Comparison between the two groups: compared with before treatment, the total scores of PANSS, positive factor, negative factor and general psychopathological symptoms in the study group and the control group decreased significantly at the 4th, 8th and 12th weekend (P0.05 or P0.01). Comparison between the two groups: the total scores of PANSS, negative factor and general psychopathological symptoms were significantly different between the study group and the control group at the end of the 12th week (P0.05 or P0.01). 2. Comparison between the two groups: compared with before treatment, the total scores of PSP in the study group and the control group decreased significantly at the end of 4, 8 and 12 weeks (P0.01); Comparison between the two groups: the study group and the control group in the 12th week PSP total score difference was statistically significant (P0.05). 3. There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). The most common adverse reactions were extrapyramidal reactions. Conclusion 1. Risperidone combined with venlafaxine can improve the negative symptoms of schizophrenia; 2. Risperidone combined with venlafaxine can improve the social function of schizophrenic patients. Risperidone combined with venlafaxine is safe and practical in the treatment of schizophrenia.
【學位授予單位】：中南大學
【學位級別】：碩士
【學位授予年份】：2012
【分類號】：R749.3

【參考文獻】

相關期刊論文 前10條

1 汪春運;去甲腎上腺素與精神藥理[J];國外醫(yī)學.精神病學分冊;2003年04期

2 王繼才;陳曉崗;;難治性精神分裂癥[J];國際精神病學雜志;2009年01期

3 王定省,高哲石,沈阿珍,何怡發(fā),吳國君,謝帆;氟西汀合并抗精神病藥物治療精神分裂癥陰性癥狀的研究[J];上海精神醫(yī)學;2000年04期

4 蔡文治;楊成龍;許海鋒;夏偉君;張呂濟;;利培酮合并舍曲林治療精神分裂癥陰性癥狀的研究[J];上海精神醫(yī)學;2006年06期

5 白漢平;;文拉法辛對慢性精神分裂癥的輔助治療作用[J];臨床精神醫(yī)學雜志;2007年05期

6 吳永輝;許維森;;聯(lián)用西酞普蘭治療精神分裂癥陰性癥狀療效分析[J];臨床精神醫(yī)學雜志;2009年01期

7 王建軍;利培酮與氯氮平合并舒必利治療精神分裂癥對照研究[J];山東精神醫(yī)學;2003年04期

8 韋群武;方貽儒;沈曉玲;田濤;廖家廣;蒙曉廣;;奎硫平、利培酮對首發(fā)精神分裂癥患者社會功能影響的對照研究[J];山東精神醫(yī)學;2006年01期

9 韓海英;唐牟尼;鄧紅;向孟澤;;住院精神分裂癥患者的生活質(zhì)量及影響因素研究[J];實用醫(yī)學雜志;2006年19期

10 李益民,李紹志,陳宇暉;利培酮聯(lián)合氟哌啶醇與單獨氯氮平治療以陽性癥狀為主的精神分裂癥的效果比較[J];四川精神衛(wèi)生;2003年04期

，

本文編號：2349756